INT315845

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.47
Pain Relevance 0.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
CSF 1
hematopoietic cells 1
D1Mit315 (Mus musculus)
D1Mit315 - T315I (2)
Pain Link Frequency Relevance Heat
Central nervous system 14 97.60 Very High Very High Very High
imagery 2 70.80 Quite High
headache 4 35.92 Quite Low
Potency 8 5.00 Very Low Very Low Very Low
corticosteroid 4 5.00 Very Low Very Low Very Low
cytokine 2 5.00 Very Low Very Low Very Low
rheumatoid arthritis 2 5.00 Very Low Very Low Very Low
cva 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Recurrence 12 97.44 Very High Very High Very High
Cancer 12 91.16 High High
Leukemia 30 87.68 High High
Myeloid Leukemia 170 85.00 Quite High
Hyperplasia 8 84.56 Quite High
Disease 14 74.48 Quite High
Vomiting 8 38.16 Quite Low
Diarrhoea 6 36.72 Quite Low
Headache 4 35.92 Quite Low
Exanthema 6 34.88 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Interestingly, dasatinib-resistant Bcr-Abl kinase mutants (T315I and V299L) were detected in the CSF leukemic blasts of two patients who developed a CNS relapse on dasatinib, suggesting that the selection of a resistant clone, rather than poor CSF penetration, was the cause of relapse.44

Dasatinib in children and adolescents

Gene_expression (detected) of T315I (T315I) in CSF associated with central nervous system and recurrence
1) Confidence 0.01 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886328 Disease Relevance 1.02 Pain Relevance 0.16
SGX393 is an azaindole which inhibits the growth of cells expressing wild type Bcr-Abl and the T315I mutant, as well as other Bcr-Abl mutants at varying concentrations.78 SGX393 also reduced CrkL phosphorylation in primary hematopoietic cells from patients harboring the T315I mutant and inhibited growth of T315I-driven tumors in mice.78 In addition, the combination of dasatinib and SGX393 completely inhibited the growth of mutant clones at most dose combinations except at intermediate concentrations of dasatinib and SGX393.78

Dasatinib cellular influx and

Gene_expression (expressing) of T315I (T315I) in hematopoietic cells associated with cancer
2) Confidence 0.01 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886328 Disease Relevance 0.45 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox